ELITE PHARMACEUTICALS INC /NV/ 8-K

What Happened

• Elite Pharmaceuticals, Inc. (ELTP) announced on August 4, 2026 via Form 8‑K (Regulation FD disclosure) that it launched a generic version of Requip XL® — Ropinirole Extended‑Release Tablets USP. The product is being marketed and sold under the Elite Laboratories, Inc. label.

Key Details

• Product: Generic Ropinirole Extended‑Release Tablets USP (Requip XL generic).
• Strengths: 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets.
• Therapeutic class: non‑ergoline dopamine agonist used to treat Parkinson’s disease.
• Filing: Press release dated August 4, 2026 furnished as Exhibit 99.1 to the Current Report on Form 8‑K.

Why It Matters

• This adds a branded generic to Elite’s commercial portfolio and expands its offerings in central nervous system therapeutics (Parkinson’s disease), which could support future product revenues.
• The 8‑K is a public disclosure only; the filing does not include sales figures, launch timing beyond the announcement, pricing, or financial guidance. Investors should watch for subsequent updates (sales data, revenue recognition, or volume trends) in future filings and press releases.